Odense C

• Effect of Camostat for Kidney Protection in Chronic Kidney Disease (CamKid). Ended
  2023-508516-34-00 4 2024-10-30 Chronic Kidney Disease with proteinuria
• Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID Ended
  2023-506949-27-00 4 2024-10-14 Secondary Osteoporosis
• A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended
  2023-505797-15-00 5 2024-09-13 SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
• Treatment of congenital nephrogenic diabetes insipidus with fluconazole an antifungal medication. Ended
  2024-517438-16-00 4 2024-09-12 Nephrogenic diabetes insipidus
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). Ended
  2023-508395-11-00 4 2024-09-10 idiopathic pulmonary fibrosis
• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat … Ended
  2023-508170-28-00 4 2024-08-07 alcohol-related liver disease
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITO … Ended
  2023-506550-20-00 10 2024-07-05 Metastatic breast cancer
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• HIV: Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Ended
  2023-505900-53-00 4 2024-04-08 HIV infection
• A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with … Ended
  2022-502457-34-00 4 2024-03-13 Triple-Negative Breast Cancer (TNBC)
• Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended
  2023-508177-85-00 5 2024-03-12 Healthy volunteers (Meningococcal infection)
• A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys’ ability … Ended
  2022-503024-27-00 5 2024-02-27 Chronic kidney disease associated with type 1 diabetes mellitus
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Ended
  2022-502453-33-00 4 2024-02-26 Advanced Endometrial Cancer
• A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or … Ended
  2023-503689-21-00 9 2023-12-05 Multiple myeloma (MM)
• A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized … Ended
  2023-504487-41-00 5 2023-11-28 COVID-19
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• The Colder Fluids Study Ended
  2023-506018-35-00 3 2023-11-06 Hemodynamic parameters is to be investigated -- comparing cold fluids
• A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended
  2022-502789-26-01 4 2023-11-03 Fibrostenotic Crohn’s Disease
• Orchid 1 Ended
  2023-503516-32-00 4 2023-10-12 Vulvar lichen sclerosus (VLS)
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 Melanoma and squamous cell carcinoma of the head and neck
• Treatment of Chronic Hand Eczema with Oral Roflumilast (HERO) Ended
  2022-503011-42-00 4 2023-09-25 Chronic hand eczema

Showing 385–408 of 467 trials